Alex Ramírez-Rincón

Alex Ramírez-Rincón

Auto-generated profile, based on publicly available information

Alex Ramírez-Rincón

Universidad Pontificia Bolivariana, Medellín, Colombia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
CYCarlos A. Yepes-Cortés
Carlos A. Yepes-Cortés
ICIsabel C. Cardenas-Moreno
Isabel C. Cardenas-Moreno
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
KFKaren M. Feriz-Bonelo
Karen M. Feriz-Bonelo
EYErica Yama-Mosquera
Erica Yama-Mosquera
CBCarlos E. Builes-Montaño
Carlos E. Builes-Montaño
Introduction Treating type 2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications. Traditionally, diabetes management has relied on stepwise medication addition based on failures in glucose control. However, the benefits and risks of combining glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remain inadequately understood. Methods This study conducted a scoping review to examine the available clinical research on the benefits and risks of combining GLP1-RAs and SGLT2is. Additionally, the nominal group technique was used to gather insights from medical experts from different areas regarding the combined therapy’s daily clinical use, concerns, and limitations. The review followed the guidelines outlined in the Joanna Briggs Institute Reviewer’s Manual and the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews). Results The final report includes 50 studies. The most common designs are observational studies. The median (IQR) number of patients across studies was 355 (1295). Studies reporting metabolic outcomes were the most common. The follow-up time ranges from 1.5 to 60 months. Although limited, the available evidence seems to support the combined use of GLP1-RAs and SGLT2is. The experts agreed that the underlying mechanisms appear synergistic rather than antagonistic for most outcomes. Conclusions Combining medical therapy is common in diabetes treatment and may occur naturally in everyday practice. Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes. Quality evidence and better-defined outcomes are paramount to guide the selection of patients for combined therapy.

13 November 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CBCarlos E. Builes-Montaño
Carlos E. Builes-Montaño
LLLaura Lema-Perez
Laura Lema-Perez
ARAlex Ramírez-Rincón
Alex Ramírez-Rincón
JZJohn J. Zuleta-Tobón
John J. Zuleta-Tobón
JRJuan C. Restrepo-Gutiérrez
Juan C. Restrepo-Gutiérrez
JGJosé García-Tirado
José García-Tirado
Most individuals with type 1 diabetes (T1D) worldwide continue to be managed with multiple daily injections or sensor-augmented pumps. Decision-support systems (DSSs) have emerged as cost-effective tools to enhance treatment adherence and glucose control. We conducted a randomized, open-label, parallel-group study to evaluate STUDIA, a DSS incorporating a digital twin-enabled simulation-assisted bolus calculator. Twenty-eight participants with T1D used either the simulation-assisted calculator or traditional carbohydrate counting for prandial insulin dosing, with glucose monitored using Freestyle Libre. After four weeks, the group using the simulation-assisted calculator showed a 7% increase in time in the target glucose range (70–180 mg/dL) compared to the control (p < 0.001), along with a lower hypoglycemia incidence rate (RR 0.31, p = 0.022). Model performance yielded a mean absolute percentage error at 60 min of 19.2 ± 6.7%, increasing at longer horizons, with most discrepancies between simulation and sensor falling into no-risk or slight-risk zones. These findings support the safety, feasibility, and potential clinical utility of the STUDIA system in people with T1D.

1 November 2016 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
ARAlex Ramirez-Rincon
Alex Ramirez-Rincon
JHJaime Hincapie-García
Jaime Hincapie-García
CAClaudia Monsalve Arango
Claudia Monsalve Arango
NANatalia Aristizabal
Natalia Aristizabal
ECEstefany Castillo
Estefany Castillo
JBJosé Fernando Botero
José Fernando Botero
Background: Type 1 diabetes can be difficult to control. Augmented pump therapy (CSII-rtCGM) has become an important tool for controlling blood glucose and decreasing hypoglycemia. Methods: Describe the results 1 year after starting CSII-rtCGM in patients with diabetes in Medellín, Colombia. This is an observational, retrospective study. Patients with type 1 and type 2 diabetes started on CSII-rtCGM between January 2008 and June 2015 were included. Qualitative variables were analyzed as absolute or relative frequencies. Quantitative variables were obtained through central tendency and dispersion according to the normal distribution of the analyzed variable using Kolmogorov–Smirnov. SPSS 19 from IBM was used. Results: Two hundred forty-seven patients were identified, of those 183 were included. The starting HbA1C was 8.7% ± 1.7% and 7.4% ± 0.8% ( P < 0.05) 1 year later. 16.5% of patients had been admitted to the hospital before starting CSII-rtCGM, after 1 year the admission rate was 6.0% ( P < 0.05). The incidence of severe hypoglycemia at the beginning was 32%, 1 year later it was 7.1%. Conclusion: CSII-rtCGM therapy improves glucose control and decreases severe hypoglycemic events and hospital admission rate.

28 April 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
ARAlex Ramírez-Rincón
Alex Ramírez-Rincón
CBCarlos E. Builes-Montaño
Carlos E. Builes-Montaño
JHJaime A. Hincapié-García
Jaime A. Hincapié-García
VBVictor M. Blanco
Victor M. Blanco
JBJosé F. Botero-Arango
José F. Botero-Arango
Background: Type 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting.Methods: An observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events.Results: 67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline.Conclusions: This real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts.

8 May 2024 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
ARAlex Ramírez-Rincón
Alex Ramírez-Rincón
DHDiana Henao-Carrillo
Diana Henao-Carrillo
MOMiguel Omeara
Miguel Omeara
JOJulio Oliveros
Julio Oliveros
JAJosé Assaf
José Assaf
MAMaría Alejandra Alzate
María Alejandra Alzate
Introduction Insulin degludec/liraglutide (IDegLira) is a fixed-ratio combination of insulin degludec (a basal insulin) and liraglutide (a glucagon-like peptide-1 receptor agonist [GLP-1RA]). This study aimed to investigate clinical outcomes in people with type 2 diabetes mellitus (T2DM) after initiating IDegLira treatment in a real-world setting in Colombia. Methods SPIRIT is a non-interventional, single-arm, retrospective chart review study to assess clinical outcomes in people with T2DM. Participating patients were switched from a treatment regimen of basal insulin (with or without oral antidiabetics [OADs]) and started on treatment with IDegLira a minimum of 26 ± 6 weeks before the data collection start date. Data were collected from the medical records of 175 patients in ten clinical centers across Colombia. Results Compared with baseline, there was a significant reduction in glycated hemoglobin (HbA1c) (1.3%; 95% confidence interval [CI] − 1.6 to − 1.0; p < 0.0001) after 26 ± 6 weeks of follow-up. The mean HbA1c at baseline and at the end of the study was 9.1% and 7.8%, respectively. In addition, IDegLira significantly reduced absolute body weight by 1 kg (95% CI − 1.5 to − 0.5; p < 0.0001), from a mean of 76.1 kg at baseline to 75.1 kg after follow-up. The mean IDegLira dose at the end of the study was 21.3 U, and no severe hypoglycemic events were observed during the follow-up period. Conclusion In real-world practice, initiating IDegLira in patients with T2DM previously treated with basal insulin (± OAD) was associated with improved glycemic control, reduced body weight and reduced risk of hypoglycemia. Trial registration ClinicalTrials.gov identifier: NCT05324462.

1 December 2021 in Endocrinología, Diabetes y Nutrición
Verified
Journal Article
Closed access
JBJosé Fernando Botero
José Fernando Botero
LVLuz Marcela Vásquez
Luz Marcela Vásquez
VBVíctor M. Blanco
Víctor M. Blanco
DCDiana Paola Cuesta
Diana Paola Cuesta
ARAlex Ramírez-Rincón
Alex Ramírez-Rincón
APAndres Palacio
Andres Palacio